DOP042: Need for ileocaecal resections, but not ileo-colic re-resections, has decreased: a nationwide study of temporal trends in Crohn surgery in Sweden 1990–2014ECCO '18 Vienna
2018
DOP043: Comparative outcomes of ileal pouch revision vs. excision for pouch failure within the American College of Surgeon National Surgical Quality Improvement ProgrammeECCO '18 Vienna
2018
DOP046: Higher serum concentrations of vedolizumab are associated with superior endoscopic outcomes in Crohn’s disease: data from the LOVE-CD trialECCO '18 Vienna
2018
DOP047: Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn’s disease: pharmacokinetic–pharmacodynamic analysis of TAILORIXECCO '18 Vienna
2018
DOP048: Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with inflammatory bowel diseaseECCO '18 Vienna
2018
DOP049: Combination therapy of cyclosporine and vedolizumab is effective and safe for severe, steroid-resistant ulcerative colitis patients: A prospective studyECCO '18 Vienna
2018
DOP050: Influence of disease location on vedolizumab efficacy in inflammatory bowel disease: a real-life multicentre experienceECCO '18 Vienna
2018
DOP051: Shorter disease duration is associated with higher response rates to vedolizumab in Crohn’s disease but not ulcerative colitis: a multi-centre consortium analysisECCO '18 Vienna
2018
DOP052: Vedolizumab vs. ustekinumab for Crohn’s disease: comparative effectiveness in a real-life observational cohort study (ICC case series)ECCO '18 Vienna
2018
DOP053: Impact of concomitant immunomodulator use on vedolizumab effectiveness: a multicentre consortium propensity score-matched analysisECCO '18 Vienna
2018
DOP054: Vedolizumab in combination with steroids for induction therapy in Crohn’s disease: an exploratory analysis of the GEMINI 2 and GEMINI 3 studiesECCO '18 Vienna
2018
DOP055: Luminal application of a GATA3-specific DNAzyme ameliorates mucosal inflammation in a randomised trial with active ulcerative colitis patientsECCO '18 Vienna
2018
DOP057: ECCO-EBMT joint paper: autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn’s disease: Summary of the ECCO-EBMT joint reviewECCO '18 Vienna
2018
DOP058: Combined stem cells and anticytokine therapy contributes to a more pronounced decrease in the degree of inflammation of the intestinal mucosa in Crohn’s diseaseECCO '18 Vienna
2018
DOP059: Combined anticytokine and local mesenchymal stem cells therapy promotes longer healing of simple fistulas in patients with Crohn’s diseaseECCO '18 Vienna
2018